Type of diabetes mellitus with high blood sugar and insulin resistance
Medical condition
Type 2 diabetes
|
---|
Other names
| Diabetes mellitus type 2;
adult-onset diabetes;
[1]
noninsulin-dependent diabetes mellitus (NIDDM)
|
---|
|
A blue circle is the universal symbol of diabetes.
[2]
|
Pronunciation
| |
---|
Specialty
| Endocrinology
|
---|
Symptoms
| Increased thirst
,
frequent urination
, unexplained
weight loss
,
increased hunger
[3]
|
---|
Complications
| Hyperosmolar hyperglycemic state
,
diabetic ketoacidosis
,
heart disease
,
stroke
,
diabetic retinopathy
,
kidney failure
,
amputations
[1]
[4]
[5]
|
---|
Usual onset
| Middle or older age
[6]
|
---|
Duration
| Long term
[6]
|
---|
Causes
| Obesity
, lack of exercise,
genetics
[1]
[6]
|
---|
Diagnostic method
| Blood test
[3]
|
---|
Prevention
| Maintaining normal weight,
exercising
, healthy diet
[1]
|
---|
Treatment
| Dietary changes
,
metformin
, insulin,
bariatric surgery
[1]
[7]
[8]
[9]
|
---|
Prognosis
| 10 year shorter
life expectancy
[10]
|
---|
Frequency
| 392 million (2015)
[11]
|
---|
Type 2 diabetes
(
T2D
), formerly known as
adult-onset diabetes
, is a form of
diabetes mellitus
that is characterized by
high blood sugar
,
insulin resistance
, and relative lack of
insulin
.
[6]
Common symptoms include
increased thirst
,
frequent urination
,
fatigue
and unexplained
weight loss
.
[3]
Symptoms may also include
increased hunger
, having a sensation of
pins and needles
, and
sores
(wounds) that do not heal.
[3]
Often symptoms come on slowly.
[6]
Long-term complications from high blood sugar include
heart disease
,
stroke
,
diabetic retinopathy
which can result in
blindness
,
kidney failure
, and poor blood flow in the limbs which may lead to
amputations
.
[1]
The sudden onset of
hyperosmolar hyperglycemic state
may occur; however,
ketoacidosis
is uncommon.
[4]
[5]
Type 2 diabetes primarily occurs as a result of
obesity
and lack of exercise.
[1]
Some people are
genetically
more at risk than others.
[6]
Type 2 diabetes makes up about 90% of cases of
diabetes
, with the other 10% due primarily to
type 1 diabetes
and
gestational diabetes
.
[1]
In type 1 diabetes there is a lower total level of insulin to control blood glucose, due to an
autoimmune
induced loss of insulin-producing
beta cells
in the
pancreas
.
[12]
[13]
Diagnosis of diabetes is by blood tests such as
fasting plasma glucose
,
oral glucose tolerance test
, or
glycated hemoglobin
(A1C).
[3]
Type 2 diabetes is largely preventable by staying at a normal weight,
exercising
regularly, and eating a healthy diet (high in fruits and vegetables and low in sugar and saturated fats).
[1]
Treatment involves exercise and
dietary changes
.
[1]
If blood sugar levels are not adequately lowered, the medication
metformin
is typically recommended.
[7]
[14]
Many people may eventually also require insulin injections.
[9]
In those on insulin, routinely checking blood sugar levels (such as through a
continuous glucose monitor
) is advised; however, this may not be needed in those who are not on insulin therapy.
[15]
Bariatric surgery
often improves diabetes in those who are obese.
[8]
[16]
Rates of type 2 diabetes have increased markedly since 1960 in parallel with obesity.
[17]
As of 2015 there were approximately 392 million people diagnosed with the disease compared to around 30 million in 1985.
[11]
[18]
Typically it begins in middle or older age,
[6]
although rates of type 2 diabetes are increasing in young people.
[19]
[20]
Type 2 diabetes is associated with a ten-year-shorter life expectancy.
[10]
Diabetes was one of the first diseases ever described, dating back to an Egyptian manuscript from
c.
1500
BCE
.
[21]
The importance of insulin in the disease was determined in the 1920s.
[22]
Signs and symptoms
The classic symptoms of diabetes are frequent urination (
polyuria
), increased thirst (
polydipsia
), increased hunger (
polyphagia
), and
weight loss
.
[23]
Other symptoms that are commonly present at diagnosis include a history of
blurred vision
,
itchiness
,
peripheral neuropathy
, recurrent
vaginal infections
, and
fatigue
.
[13]
Other symptoms may include
loss of taste
.
[24]
Many people, however, have no symptoms during the first few years and are diagnosed on routine testing.
[13]
A small number of people with type 2 diabetes can develop a
hyperosmolar hyperglycemic state
(a condition of very high blood sugar associated with a
decreased level of consciousness
and
low blood pressure
).
[13]
Complications
Type 2 diabetes is typically a chronic disease associated with a ten-year-shorter life expectancy.
[10]
[25]
This is partly due to a number of complications with which it is associated, including: two to four times the risk of
cardiovascular disease
, including
ischemic heart disease
and
stroke
; a 20-fold increase in lower limb
amputations
, and increased rates of
hospitalizations
.
[10]
In the developed world, and increasingly elsewhere, type 2 diabetes is the largest cause of nontraumatic
blindness
and
kidney failure
.
[26]
It has also been associated with an increased risk of
cognitive dysfunction
and
dementia
through disease processes such as
Alzheimer's disease
and
vascular dementia
.
[27]
Other complications include hyperpigmentation of skin (
acanthosis nigricans
),
sexual dysfunction
,
diabetic ketoacidosis
, and frequent infections.
[23]
[28]
[29]
There is also an association between type 2 diabetes and mild hearing loss.
[30]
Causes
The development of type 2 diabetes is caused by a combination of lifestyle and genetic factors.
[26]
[31]
While some of these factors are under personal control, such as
diet
and
obesity
, other factors are not, such as increasing age, female sex, and genetics.
[10]
Generous consumption of alcohol is also a risk factor.
[32]
Obesity is more common in women than men in many parts of Africa.
[33]
The
nutritional
status of a mother during fetal development may also play a role, with one proposed mechanism being that of
DNA methylation
.
[34]
The intestinal bacteria
Prevotella copri
and
Bacteroides vulgatus
have been connected with type 2 diabetes.
[35]
Lifestyle
Lifestyle factors are important to the development of type 2 diabetes, including obesity and being
overweight
(defined by a
body mass index
of greater than 25), lack of physical activity, poor diet,
psychological stress
, and
urbanization
.
[10]
[36]
Excess body fat is associated with 30% of cases in those of Chinese and Japanese descent, 60?80% of cases in those of European and African descent, and 100% of cases in
Pima Indians
and
Pacific Islanders
.
[13]
Among those who are not obese, a high
waist?hip ratio
is often present.
[13]
Smoking appears to increase the risk of type 2 diabetes.
[37]
A lack of sleep
has also been linked
to type 2 diabetes.
[38]
Laboratory studies have linked short-term sleep deprivations to changes in glucose metabolism, nervous system activity, or hormonal factors that may lead to diabetes.
[38]
Dietary factors also influence the risk of developing type 2 diabetes. Consumption of sugar-sweetened drinks in excess is associated with an increased risk.
[39]
[40]
The type of fats in the diet are important, with
saturated fats
and
trans fatty acids
increasing the risk, and
polyunsaturated
and
monounsaturated fat
decreasing the risk.
[31]
Eating a lot of
white rice
appears to play a role in increasing risk.
[41]
A lack of exercise is believed to cause 7% of cases.
[42]
Persistent organic pollutants
may also play a role.
[43]
Genetics
Most cases of diabetes involve many
genes
, with each being a small contributor to an increased probability of becoming a type 2 diabetic.
[10]
The proportion of diabetes that is
inherited
is estimated at 72%.
[44]
More than 36 genes and 80
single nucleotide polymorphisms
(SNPs) had been found that contribute to the risk of type 2 diabetes.
[45]
[46]
All of these genes together still only account for 10% of the total heritable component of the disease.
[45]
The
TCF7L2
allele
, for example, increases the risk of developing diabetes by 1.5 times and is the greatest risk of the common genetic variants.
[13]
Most of the genes linked to diabetes are involved in pancreatic
beta cell
functions.
[13]
There are a number of rare cases of diabetes that arise due to an abnormality in a single gene (known as
monogenic
forms of diabetes or
"other specific types of diabetes"
).
[10]
[13]
These include
maturity onset diabetes of the young
(MODY),
Donohue syndrome
, and
Rabson?Mendenhall syndrome
, among others.
[10]
Maturity onset diabetes of the young constitute 1?5% of all cases of diabetes in young people.
[47]
Epigenetics
Epigenetic
regulation occurs at multiple levels including (1) direct
methylation
of
cytosine
and
adenine
residues in
DNA
, (2) covalent modification of
histone
proteins in
chromatin
, and (3) action of non coding
microRNAs
(for other examples, see Wikipedia article "
Epigenetics
"). On November 17?19, 2017, the American Diabetes Association held a research symposium entitled "Epigenetics and Epigenomics: Implications for Diabetes and Obesity." As a result of this symposium, an overview of the state of the field was presented in which it was noted that over 1,000 research articles have been published that address the intersection of diabetes and epigenetics or epigenomics.
[48]
The current state of knowledge in this field is addressed the Wikipedia article "
Epigenetics of diabetes Type 2
."
Medical conditions
There are a number of medications and other health problems that can predispose to diabetes.
[49]
Some of the medications include:
glucocorticoids
,
thiazides
,
beta blockers
,
atypical antipsychotics
,
[50]
and
statins
.
[51]
Those who have previously had
gestational diabetes
are at a higher risk of developing type 2 diabetes.
[23]
Other health problems that are associated include:
acromegaly
,
Cushing's syndrome
,
hyperthyroidism
,
pheochromocytoma
, and certain
cancers
such as
glucagonomas
.
[49]
Individuals with cancer may be at a higher risk of mortality if they also have diabetes.
[52]
Testosterone deficiency
is also associated with type 2 diabetes.
[53]
[54]
Eating disorders
may also interact with type 2 diabetes, with
bulimia nervosa
increasing the risk and
anorexia nervosa
decreasing it.
[55]
Pathophysiology
Type 2 diabetes is due to insufficient insulin production from
beta cells
in the setting of
insulin resistance
.
[13]
Insulin resistance, which is the inability of
cells
to respond adequately to normal levels of insulin, occurs primarily within the muscles,
liver
, and fat tissue.
[59]
In the liver, insulin normally suppresses
glucose
release. However, in the setting of insulin resistance, the liver inappropriately releases glucose into the blood.
[10]
The proportion of insulin resistance versus beta cell dysfunction differs among individuals, with some having primarily insulin resistance and only a minor defect in insulin secretion and others with slight insulin resistance and primarily a lack of insulin secretion.
[13]
Other potentially important mechanisms associated with type 2 diabetes and insulin resistance include: increased breakdown of
lipids
within
fat cells
, resistance to and lack of
incretin
, high
glucagon
levels in the blood, increased retention of salt and water by the kidneys, and inappropriate regulation of metabolism by the
central nervous system
.
[10]
However, not all people with insulin resistance develop diabetes since an impairment of insulin secretion by pancreatic beta cells is also required.
[13]
In the early stages of insulin resistance, the mass of beta cells expands, increasing the output of insulin to compensate for the insulin insensitivity, so that the
disposition index
remains constant.
[60]
But when type 2 diabetes has become manifest, a type 2 diabetic will have lost about half of their beta cells.
[60]
Fatty acids
in the beta cells activate
FOXO1
, resulting in apoptosis of the beta cells.
[60]
The disposition index drops and diabetes becomes manifest.
The causes of the aging-related insulin resistance seen in obesity and in type 2 diabetes are uncertain. Effects of intracellular lipid metabolism and ATP production in liver and muscle cells may contribute to insulin resistance.
[61]
New evidence also points to a role of a brain region called the
hypothalamus
in the development of insulin resistance. A gene called
Dusp8
is linked with an increased risk for diabetes.
[62]
This gene codes for a protein that regulates neuronal signaling in the hypothalamus. Also, infusions into the hypothalamus of a hormone called leptin normalize blood glucose and diminish insulin resistance in diabetic animals.
[63]
Activation of hypothalamic cells by
leptin
has an important role in maintaining normal levels of blood glucose. Thus, both the
endocrine
cells of the pancreas AND cells in the
hypothalamus
may have a role in the etiology of type 2 diabetes.
Hypothalamic cells regulate blood glucose via projections to the
autonomic nervous system
. Autonomic innervation of liver and muscle cells stimulates an increased uptake of glucose. In diabetic humans, the control of blood glucose by the autonomic nervous system is abnormal.
[64]
Leptin-sensitive, glucose regulating neurons become resistant to leptin during aging or during exposure to a high-fat diet. These leptin-resistant neurons fail to restrain food intake, obesity, and blood glucose. The reasons for this lowered responsiveness to leptin are uncertain and are part of the puzzle of the causes of type 2 diabetes.
[65]
Blood glucose levels can also be normalized in diabetic rodents by a single intrahypothalamic infusion of Fibroblast Growth Factor 1 (
FGF1
), an effect that persists for months even in severely diabetic animals. This remarkable cure of diabetes is accomplished by a stimulation of accessory brain cells called
astrocytes
.
[66]
[67]
Hypothalamic astrocytes that produce Fatty Acid Binding Protein 7 (
FABP7
) are targets of FGF1; these cells are also in close contact with leptin-sensitive neurons, influence their function, and regulate leptin sensitivity.
[68]
[69]
An abnormal function of FABP7+ astrocytes thus may contribute to the resistance to leptin and insulin that appear during aging and during exposure to high-fat diets.
During aging, FABP7+ astrocytes develop cytoplasmic granules derived from degenerating
mitochondria
. This mitochondrial degeneration is partly due to the
oxidative stress
of the heightened amounts of fatty acids that are taken up by these cells and oxidized within mitochondria.
[70]
[71]
A pathological degeneration of mitochondria in these cells may compromise their normal functions and contribute to abnormalities in the control of blood glucose by the hypothalamus.
Diagnosis
The
World Health Organization
definition of diabetes (both type 1 and type 2) is for a single raised glucose reading with symptoms, otherwise raised values on two occasions, of either:
[74]
- fasting plasma glucose ≥ 7.0 mmol/L (126 mg/dL)
- or
A random blood sugar of greater than 11.1 mmol/L (200 mg/dL) in association with typical symptoms
[23]
or a
glycated hemoglobin
(HbA
1c
) of ≥ 48 mmol/mol (≥ 6.5
DCCT
%) is another method of diagnosing diabetes.
[10]
In 2009 an International Expert Committee that included representatives of the
American Diabetes Association
(ADA), the International Diabetes Federation (IDF), and the European Association for the Study of Diabetes (EASD) recommended that a threshold of ≥ 48 mmol/mol (≥ 6.5 DCCT %) should be used to diagnose diabetes.
[75]
This recommendation was adopted by the American Diabetes Association in 2010.
[76]
Positive tests should be repeated unless the person presents with typical symptoms and blood sugars >11.1 mmol/L (>200 mg/dL).
[75]
ADA diabetes diagnostic criteria in 2015
[77]
|
Diabetes mellitus
|
Prediabetes
|
HbA
1c
|
≥6.5%
|
5.7?6.4%
|
Fasting glucose
|
≥126 mg/dL
|
100?125 mg/dL
|
2h glucose
|
≥200 mg/dL
|
140?199 mg/dL
|
Random glucose with classic symptoms
|
≥200 mg/dL
|
Not available
|
Threshold for diagnosis of diabetes is based on the relationship between results of glucose tolerance tests, fasting glucose or HbA
1c
and complications such as
retinal problems
.
[10]
A fasting or random blood sugar is preferred over the glucose tolerance test, as they are more convenient for people.
[10]
HbA
1c
has the advantages that fasting is not required and results are more stable but has the disadvantage that the test is more costly than measurement of blood glucose.
[78]
It is estimated that 20% of people with diabetes in the United States do not realize that they have the disease.
[10]
Type 2 diabetes is characterized by high blood glucose in the context of insulin resistance and relative insulin deficiency.
[79]
This is in contrast to
type 1 diabetes
in which there is an absolute insulin deficiency due to destruction of
islet
cells in the pancreas and
gestational diabetes
that is a new onset of high blood sugars associated with pregnancy.
[13]
Type 1 and type 2 diabetes can typically be distinguished based on the presenting circumstances.
[75]
If the diagnosis is in doubt
antibody
testing may be useful to confirm type 1 diabetes and
C-peptide
levels may be useful to confirm type 2 diabetes,
[80]
with C-peptide levels normal or high in type 2 diabetes, but low in type 1 diabetes.
[81]
Screening
Universal
screening
for diabetes in people without risk factors or symptoms is not recommended.
[82]
[83]
Screening is recommended by the
World Health Organization
, the
United States Preventive Services Task Force
(USPSTF), and the
American Diabetes Association
for high-risk adults.
[84]
[85]
[86]
Risk factors considered by the USPSTF include adults over 35 years old who are overweight or have obesity and adults without symptoms whose
blood pressure
is greater than 135/80 mmHg.
[87]
[
needs update
]
[84]
For those whose blood pressure is less, the evidence is insufficient to recommend for or against screening.
[87]
[
needs update
]
The American Diabetes Society recommends screening for adults with a body mass index (BMI) over 25.
[86]
For people of Asian descent, screening is recommended if they have a BMI over 23.
[86]
Other high risk groups include people with a
first degree relative
with diabetes; some ethnic groups, including Hispanics, African-Americans, and Native-Americans; a history of
gestational diabetes
;
polycystic ovary syndrome
; excess weight; and conditions associated with
metabolic syndrome
.
[23]
There is no evidence that screening changes the risk of death and any benefit of screening on adverse effects, incidence of type 2 diabetes, HbA
1c
or socioeconomic effects are not clear.
[83]
[88]
In the UK,
NICE
guidelines suggest taking action to prevent diabetes for people with a body mass index (BMI) of 30 or more.
[89]
For people of
Black African
,
African-Caribbean
,
South Asian
and
Chinese
descent the recommendation to start prevention starts at the BMI of 27,5.
[89]
A study based on a large sample of people in England suggest even lower BMIs for certain ethnic groups for the start of prevention, for example 24 in South Asian and 21 in
Bangladeshi
populations.
[90]
[91]
Prevention
Onset of type 2 diabetes can be delayed or prevented through proper nutrition and regular exercise.
[92]
[93]
Intensive lifestyle measures may reduce the risk by over half.
[26]
[94]
The benefit of exercise occurs regardless of the person's initial weight or subsequent weight loss.
[95]
High levels of physical activity reduce the risk of diabetes by about 28%.
[96]
Evidence for the benefit of dietary changes alone, however, is limited,
[97]
with some evidence for a diet high in green leafy vegetables
[98]
and some for limiting the intake of sugary drinks.
[99]
There is an association between higher intake of sugar-sweetened fruit juice and diabetes, but no evidence of an association with 100% fruit juice.
[100]
A 2019 review found evidence of benefit from
dietary fiber
.
[101]
In those with
impaired glucose tolerance
, a 2019
systematic review
found moderate-quality evidence that
metformin
, when compared to diet and exercise or a
placebo
intervention, appeared to delay or reduce the risk of developing type 2 diabetes.
[102]
This same review found moderate-quality evidence that when compared to intensive diet and exercise, Metformin did not reduce risk of developing type 2 diabetes, as well as very low-quality evidence that combining metformin with intensive diet and exercise does not appear to have any effect on risk of developing type 2 diabetes when compared to intensive diet and exercise alone.
[102]
This systematic review only found one suitable trial comparing metformin with
sulphonylurea
in reducing risk of type 2 diabetes but it did not report any patient-relevant outcomes.
[102]
A
Cochrane
systematic review
assessed the effect of
alpha-glucosidase inhibitors
in people with impaired
glucose tolerance
, impaired
fasting blood glucose
, elevated
glycated hemoglobin A1c
(HbA1c).
[103]
It was found that
acarbose
appeared to reduce incidence of diabetes mellitus type 2 when compared to placebo, however there was no conclusive evidence that acarbose compare to diet and exercise,
metformin
,
placebo
, no intervention improved
all-cause mortality
, reduced or increased risk of cardiovascular mortality, serious or non-serious adverse events, non-fatal
stroke
,
congestive heart failure
, or non-fatal
myocardial infarction
.
[103]
The same review found that there was no conclusive evidence that voglibose compared to diet and exercise or placebo reduced incidence of diabetes mellitus type 2, or any of the other measured outcomes.
[103]
A 2017 review found that, long term, lifestyle changes decreased the risk by 28%, while medication does not reduce risk after withdrawal.
[104]
While low
vitamin D
levels are associated with an increased risk of diabetes, correcting the levels by supplementing vitamin D3 does not improve that risk.
[105]
Management
Management of type 2 diabetes focuses on lifestyle interventions, lowering other cardiovascular risk factors, and maintaining blood glucose levels in the normal range.
[26]
Self-monitoring of blood glucose for people with newly diagnosed type 2 diabetes may be used in combination with education,
[106]
although the benefit of self-monitoring in those not using multi-dose insulin is questionable.
[26]
In those who do not want to measure blood levels, measuring urine levels may be done.
[107]
Managing other cardiovascular risk factors, such as
hypertension
,
high cholesterol
, and
microalbuminuria
, improves a person's life expectancy.
[26]
Decreasing the systolic blood pressure to less than 140 mmHg is associated with a lower risk of death and better outcomes.
[108]
Intensive blood pressure management (less than 130/80 mmHg) as opposed to standard blood pressure management (less than 140-160 mmHg systolic to 85?100 mmHg diastolic) results in a slight decrease in stroke risk but no effect on overall risk of death.
[109]
Intensive blood sugar lowering (HbA
1c
<6%) as opposed to standard blood sugar lowering (HbA
1c
of 7?7.9%) does not appear to change mortality.
[110]
[111]
The goal of treatment is typically an HbA
1c
of 7 to 8% or a fasting glucose of less than 7.2 mmol/L (130 mg/dL); however these goals may be changed after professional clinical consultation, taking into account particular risks of
hypoglycemia
and life expectancy.
[86]
[112]
[113]
Hypoglycemia is associated with adverse outcomes in older people with type 2 diabetes.
[114]
Despite guidelines recommending that intensive blood sugar control be based on balancing immediate harms with long-term benefits, many people ? for example people with a life expectancy of less than nine years who will not benefit, are
over-treated
.
[115]
It is recommended that all people with type 2 diabetes get regular
eye examinations
.
[13]
There is moderate evidence suggesting that treating
gum disease
by
scaling and root planing
results in an improvement in blood sugar levels for people with diabetes.
[116]
Lifestyle
Exercise
A proper diet and regular exercise are foundations of diabetic care,
[23]
with one review indicating that a greater amount of exercise improved outcomes.
[117]
Regular exercise may improve blood sugar control, decrease body fat content, and decrease blood lipid levels.
[118]
Diet
Calorie restriction
to promote weight loss is generally recommended.
[119]
[77]
Around 80 percent of obese people with type 2 diabetes achieve complete remission with no need for medication if they sustain a weight loss of at least 15 kilograms (33 lb),
[120]
[121]
but most patients are not able to achieve or sustain significant weight loss.
[122]
Even modest weight loss can produce significant improvements in glycemic control and reduce the need for medication.
[123]
Several diets may be effective such as the
Dietary Approaches to Stop Hypertension
(DASH),
Mediterranean diet
,
low-fat diet
, or
monitored carbohydrate diets
such as a
low carbohydrate diet
.
[77]
[124]
[125]
Other recommendations include emphasizing intake of fruits, vegetables, reduced saturated fat and low-fat dairy products, and with a macronutrient intake tailored to the individual, to distribute calories and carbohydrates throughout the day.
[77]
[126]
A 2021 review showed that consumption of tree nuts (
walnuts
,
almonds
, and
hazelnuts
) reduced fasting blood glucose in diabetic people.
[127]
As of 2015
[update]
, there is insufficient data to recommend nonnutritive sweeteners, which may help reduce caloric intake.
[128]
An elevated intake of
microbiota-accessible carbohydrates
can help reducing the effects of T2D.
[129]
Viscous fiber supplements
may be useful in those with diabetes.
[130]
Culturally appropriate education may help people with type 2 diabetes control their blood sugar levels for up to 24 months.
[131]
There is not enough evidence to determine if lifestyle interventions affect mortality in those who already have type 2 diabetes.
[94]
Stress management
Although psychological stress is recognized as a risk factor for type 2 diabetes,
[10]
the effect of
stress management
interventions on disease progression are not established.
[132]
A
Cochrane review
is under way to assess the effects of
mindfulness
?based interventions for adults with type 2 diabetes.
[133]
Medications
Blood sugar control
There are several classes of
anti-diabetic medications
available.
Metformin
is generally recommended as a first line treatment as there is some evidence that it decreases mortality;
[7]
[26]
[134]
however, this conclusion is questioned.
[135]
Metformin should not be used in those with severe kidney or liver problems.
[23]
The
American Diabetes Association
and
European Association for the Study of Diabetes
recommend using a
GLP-1 receptor agonist
or
SGLT2 inhibitor
as the first-line treatment in patients who have or are at high risk for
atherosclerotic cardiovascular disease
,
heart failure
, or kidney disease.
[136]
[137]
The higher cost of these drugs compared to metformin has limited their use.
[122]
[138]
[139]
A second oral agent of another class or insulin may be added if metformin is not sufficient after three months.
[112]
Other classes of medications include:
sulfonylureas
,
thiazolidinediones
,
dipeptidyl peptidase-4 inhibitors
, SGLT2 inhibitors, and GLP-1 receptor agonists.
[112]
A 2018 review found that SGLT2 inhibitors and GLP-1 agonists, but not DPP-4 inhibitors, were associated with lower mortality than placebo or no treatment.
[140]
Rosiglitazone
, a thiazolidinedione, has not been found to improve long-term outcomes even though it improves blood sugar levels.
[141]
Additionally it is associated with increased rates of heart disease and death.
[142]
Injections of insulin may either be added to oral medication or used alone.
[26]
Most people do not initially need insulin.
[13]
When it is used, a long-acting formulation is typically added at night, with oral medications being continued.
[23]
[26]
Doses are then increased to effect (blood sugar levels being well controlled).
[26]
When nightly insulin is insufficient, twice daily insulin may achieve better control.
[23]
The long acting insulins
glargine
and
detemir
are equally safe and effective,
[143]
and do not appear much better than neutral protamine Hagedorn
(NPH) insulin
, but as they are significantly more expensive, they are not cost effective as of 2010.
[144]
In those who are
pregnant
, insulin is generally the treatment of choice.
[23]
Blood pressure lowering
Many international guidelines recommend blood pressure treatment targets that are lower than 140/90 mmHg for people with diabetes.
[145]
However, there is only limited evidence regarding what the lower targets should be. A 2016 systematic review found potential harm to treating to targets lower than 140 mmHg,
[146]
and a subsequent review in 2019 found no evidence of additional benefit from blood pressure lowering to between 130?140mmHg, although there was an increased risk of adverse events.
[147]
2015 American Diabetes Association recommendations are that people with diabetes and albuminuria should receive an inhibitor of the renin-angiotensin system to reduce the risks of progression to end-stage renal disease, cardiovascular events, and death.
[77]
There is some evidence that
angiotensin converting enzyme inhibitors
(ACEIs) are superior to other inhibitors of the renin-angiotensin system such as
angiotensin receptor blockers
(ARBs),
[148]
or
aliskiren
in preventing cardiovascular disease.
[149]
Although a more recent review found similar effects of ACEIs and ARBs on major cardiovascular and renal outcomes.
[150]
There is no evidence that combining ACEIs and ARBs provides additional benefits.
[150]
Other
The use of
aspirin
to prevent cardiovascular disease in diabetes is controversial.
[77]
Aspirin is recommended in people at high risk of cardiovascular disease, however routine use of aspirin has not been found to improve outcomes in uncomplicated diabetes.
[151]
2015 American Diabetes Association recommendations for aspirin use (based on expert consensus or clinical experience) are that low-dose aspirin use is reasonable in adults with diabetes who are at intermediate risk of cardiovascular disease (10-year cardiovascular disease risk, 5?10%).
[77]
Vitamin D
supplementation to people with type 2 diabetes may improve markers of insulin resistance and HbA1c.
[152]
Sharing their
electronic health records
with people who have type 2 diabetes helps them to reduce their blood sugar levels. It is a way of helping people understand their own health condition and involving them actively in its management.
[153]
[154]
Surgery
Weight loss surgery
in those who are obese is an effective measure to treat diabetes.
[155]
Many are able to maintain normal blood sugar levels with little or no medication following surgery
[156]
and long-term mortality is decreased.
[157]
There however is some short-term mortality risk of less than 1% from the surgery.
[158]
The
body mass index
cutoffs for when surgery is appropriate are not yet clear.
[157]
It is recommended that this option be considered in those who are unable to get both their weight and blood sugar under control.
[159]
[160]
Epidemiology
The
International Diabetes Federation
estimates nearly 537 million people lived with diabetes worldwide in 2021,
90?95% of whom have type 2 diabetes.
Diabetes is common both in the
developed
and the
developing world
.
[10]
Some ethnic groups such as
South Asians
,
Pacific Islanders
,
Latinos
, and
Native Americans
are at particularly high risk of developing type 2 diabetes.
[23]
Type 2 diabetes in normal weight individuals represents 60 to 80 percent of all cases in some Asian countries. The mechanism causing diabetes in non-obese individuals is poorly understood.
[163]
[164]
[165]
Rates of diabetes in 1985 were estimated at 30 million, increasing to 135 million in 1995 and 217 million in 2005.
[18]
This increase is believed to be primarily due to the global population aging, a decrease in exercise, and increasing rates of obesity.
[18]
Traditionally considered a disease of adults, type 2 diabetes is increasingly diagnosed in children in parallel with rising
obesity
rates.
[10]
The five countries with the greatest number of people with diabetes as of 2000 are India having 31.7 million, China 20.8 million, the United States 17.7 million, Indonesia 8.4 million, and Japan 6.8 million.
[166]
It is recognized as a global
epidemic
by the
World Health Organization
.
[1]
History
Diabetes is one of the first diseases described
[21]
with an Egyptian manuscript from
c.
1500
BCE
mentioning "too great emptying of the urine."
[167]
[168]
The first described cases are believed to be of type 1 diabetes.
[167]
Indian physicians around the same time identified the disease and classified it as
madhumeha
or
honey urine
noting that the urine would attract ants.
[167]
The term "diabetes" or "to pass through" was first used in 230 BCE by the Greek
Apollonius Memphites
.
[167]
The disease was rare during the time of the
Roman empire
with
Galen
commenting that he had only seen two cases during his career.
[167]
Type 1 and type 2 diabetes were identified as separate conditions for the first time by the Indian physicians
Sushruta
and
Charaka
in 400?500 AD with type 1 associated with youth and type 2 with being overweight.
[167]
Effective treatment was not developed until the early part of the 20th century when the Canadians
Frederick Banting
and
Charles Best
discovered insulin in 1921 and 1922.
[167]
This was followed by the development of the long acting NPH insulin in the 1940s.
[167]
In 1916, Elliot Joslin proposed that in people with diabetes, periods of fasting are helpful.
[169]
Subsequent research has supported this, and weight loss is a first line treatment in type 2 diabetes.
[169]
Research
Researchers developed the Diabetes Severity Score (DISSCO), a tool that might better than the standard blood test at identify if a person's condition is declining.
[170]
[171]
It uses a computer algorithm to analyse data from anonymised electronic patient records and produces a score based on 34 indicators.
[172]
[173]
References
- ^
a
b
c
d
e
f
g
h
i
j
k
"Diabetes Fact sheet N°312"
.
World Health Organization
. August 2011. Archived from
the original
on 26 August 2013
. Retrieved
2012-01-09
.
- ^
"Diabetes Blue Circle Symbol"
. International Diabetes Federation. 17 March 2006. Archived from
the original
on 5 August 2007.
- ^
a
b
c
d
e
"Diagnosis of Diabetes and Prediabetes"
.
National Institute of Diabetes and Digestive and Kidney Diseases
. June 2014. Archived from
the original
on 6 March 2016
. Retrieved
10 February
2016
.
- ^
a
b
Pasquel FJ, Umpierrez GE (November 2014).
"Hyperosmolar hyperglycemic state: a historic review of the clinical presentation, diagnosis, and treatment"
.
Diabetes Care
.
37
(11): 3124?31.
doi
:
10.2337/dc14-0984
.
PMC
4207202
.
PMID
25342831
.
- ^
a
b
Fasanmade OA, Odeniyi IA, Ogbera AO (June 2008). "Diabetic ketoacidosis: diagnosis and management".
African Journal of Medicine and Medical Sciences
.
37
(2): 99?105.
PMID
18939392
.
- ^
a
b
c
d
e
f
g
"Causes of Diabetes"
.
National Institute of Diabetes and Digestive and Kidney Diseases
. June 2014.
Archived
from the original on 2 February 2016
. Retrieved
10 February
2016
.
- ^
a
b
c
Maruthur NM, Tseng E, Hutfless S, Wilson LM, Suarez-Cuervo C, Berger Z, et al. (June 2016). "Diabetes Medications as Monotherapy or Metformin-Based Combination Therapy for Type 2 Diabetes: A Systematic Review and Meta-analysis".
Annals of Internal Medicine
.
164
(11): 740?51.
doi
:
10.7326/M15-2650
.
PMID
27088241
.
S2CID
32016657
.
- ^
a
b
Cetinkunar S, Erdem H, Aktimur R, Sozen S (June 2015).
"Effect of bariatric surgery on humoral control of metabolic derangements in obese patients with type 2 diabetes mellitus: How it works"
.
World Journal of Clinical Cases
.
3
(6): 504?9.
doi
:
10.12998/wjcc.v3.i6.504
.
PMC
4468896
.
PMID
26090370
.
- ^
a
b
Krentz AJ, Bailey CJ (February 2005). "Oral antidiabetic agents: current role in type 2 diabetes mellitus".
Drugs
.
65
(3): 385?411.
doi
:
10.2165/00003495-200565030-00005
.
PMID
15669880
.
S2CID
29670619
.
- ^
a
b
c
d
e
f
g
h
i
j
k
l
m
n
o
p
q
r
Melmed S, Polonsky KS, Larsen PR, Kronenberg HM, eds. (2011).
Williams textbook of endocrinology
(12th ed.). Philadelphia: Elsevier/Saunders. pp. 1371?1435.
ISBN
978-1-4377-0324-5
.
- ^
a
b
Vos T, Allen C, Arora M, Barber RM, Bhutta ZA, Brown A, et al. (GBD 2015 Disease and Injury Incidence and Prevalence Collaborators) (October 2016).
"Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015"
.
Lancet
.
388
(10053): 1545?1602.
doi
:
10.1016/S0140-6736(16)31678-6
.
PMC
5055577
.
PMID
27733282
.
- ^
MacKay I, Rose N, eds. (2014).
The Autoimmune Diseases
. Academic Press. p. 575.
ISBN
978-0-12-384929-8
.
OCLC
965646175
.
- ^
a
b
c
d
e
f
g
h
i
j
k
l
m
n
o
Gardner DG, Shoback D, eds. (2011). "Chapter 17: Pancreatic hormones & diabetes mellitus".
Greenspan's basic & clinical endocrinology
(9th ed.). New York: McGraw-Hill Medical.
ISBN
978-0-07-162243-1
.
OCLC
613429053
.
- ^
Saenz A, Fernandez-Esteban I, Mataix A, Ausejo M, Roque M, Moher D (July 2005). Saenz A (ed.). "Metformin monotherapy for type 2 diabetes mellitus".
The Cochrane Database of Systematic Reviews
(3): CD002966.
doi
:
10.1002/14651858.CD002966.pub3
.
PMID
16034881
.
(Retracted)
- ^
Malanda UL, Welschen LM, Riphagen II, Dekker JM, Nijpels G, Bot SD (January 2012).
"Self-monitoring of blood glucose in patients with type 2 diabetes mellitus who are not using insulin"
.
The Cochrane Database of Systematic Reviews
.
1
: CD005060.
doi
:
10.1002/14651858.CD005060.pub3
.
hdl
:
1871/48558
.
PMID
22258959
.
S2CID
205176936
.
- ^
Ganguly S, Tan HC, Lee PC, Tham KW (April 2015).
"Metabolic bariatric surgery and type 2 diabetes mellitus: an endocrinologist's perspective"
.
Journal of Biomedical Research
.
29
(2): 105?11.
doi
:
10.7555/JBR.29.20140127
.
PMC
4389109
.
PMID
25859264
.
- ^
Moscou S (2013). "Getting the word out: advocacy, social marketing, and policy development and enforcement". In Truglio-Londrigan M, Lewenson SB (eds.).
Public health nursing: practicing population-based care
(2nd ed.). Burlington, MA: Jones & Bartlett Learning. p.
317
.
ISBN
978-1-4496-4660-8
.
OCLC
758391750
.
- ^
a
b
c
Smyth S, Heron A (January 2006). "Diabetes and obesity: the twin epidemics".
Nature Medicine
.
12
(1): 75?80.
doi
:
10.1038/nm0106-75
.
PMID
16397575
.
S2CID
1042625
.
- ^
Tfayli H, Arslanian S (March 2009).
"Pathophysiology of type 2 diabetes mellitus in youth: the evolving chameleon"
.
Arquivos Brasileiros de Endocrinologia e Metabologia
.
53
(2): 165?74.
doi
:
10.1590/s0004-27302009000200008
.
PMC
2846552
.
PMID
19466209
.
- ^
Imperatore G, Boyle JP, Thompson TJ, Case D, Dabelea D, Hamman RF, et al. (December 2012).
"Projections of type 1 and type 2 diabetes burden in the U.S. population aged <20 years through 2050: dynamic modeling of incidence, mortality, and population growth"
.
Diabetes Care
.
35
(12): 2515?20.
doi
:
10.2337/dc12-0669
.
PMC
3507562
.
PMID
23173134
.
- ^
a
b
Leutholtz BC, Ripoll I (2011).
"Diabetes"
.
Exercise and disease management
(2nd ed.). Boca Raton: CRC Press. p. 25.
ISBN
978-1-4398-2759-8
.
OCLC
725919496
.
- ^
Zaccardi F, Webb DR, Yates T, Davies MJ (February 2016). "Pathophysiology of type 1 and type 2 diabetes mellitus: a 90-year perspective".
Postgraduate Medical Journal
.
92
(1084): 63?9.
doi
:
10.1136/postgradmedj-2015-133281
.
PMID
26621825
.
S2CID
28169759
.
- ^
a
b
c
d
e
f
g
h
i
j
k
Vijan S (March 2010). "In the clinic. Type 2 diabetes".
Annals of Internal Medicine
.
152
(5): ITC31?15, quiz ITC316.
doi
:
10.7326/0003-4819-152-5-201003020-01003
.
PMID
20194231
.
S2CID
207535925
.
- ^
Rathee M, Prachi J (2019).
"Ageusia"
.
StatPearls
. StatPearls Publishing.
PMID
31747182
.
- ^
"Developing tools to help predict future risk for diabetes and heart attack"
.
Faculty of Biology, Medicine and Health
. Retrieved
2024-03-20
.
- ^
a
b
c
d
e
f
g
h
i
j
Ripsin CM, Kang H, Urban RJ (January 2009). "Management of blood glucose in type 2 diabetes mellitus".
American Family Physician
.
79
(1): 29?36.
PMID
19145963
.
- ^
Pasquier F (October 2010). "Diabetes and cognitive impairment: how to evaluate the cognitive status?".
Diabetes & Metabolism
.
36
(Suppl 3): S100-5.
doi
:
10.1016/S1262-3636(10)70475-4
.
PMID
21211730
.
- ^
"Diabetic ketoacidosis: Know the warning signs-Diabetic ketoacidosis - Symptoms & causes"
.
Mayo Clinic
. Retrieved
2024-03-20
.
- ^
"WHAT IS TYPE 2 DIABETES?"
.
Diabetes Daily
. December 29, 2021.
Archived
from the original on 2024-03-19
. Retrieved
2024-03-20
.
- ^
Akinpelu OV, Mujica-Mota M, Daniel SJ (March 2014). "Is type 2 diabetes mellitus associated with alterations in hearing? A systematic review and meta-analysis".
The Laryngoscope
.
124
(3): 767?776.
doi
:
10.1002/lary.24354
.
PMID
23945844
.
S2CID
25569962
.
- ^
a
b
Riserus U,
Willett WC
, Hu FB (January 2009).
"Dietary fats and prevention of type 2 diabetes"
.
Progress in Lipid Research
.
48
(1): 44?51.
doi
:
10.1016/j.plipres.2008.10.002
.
PMC
2654180
.
PMID
19032965
.
- ^
Olokoba AB, Obateru OA, Olokoba LB (July 7, 2012).
"Type 2 Diabetes Mellitus: A Review of Current Trends"
.
Oman Medical Journal
.
27
(4): 269?273.
doi
:
10.5001/omj.2012.68
.
ISSN
1999-768X
.
PMC
3464757
.
PMID
23071876
.
- ^
Hilawe EH, Yatsuya H, Kawaguchi L, Aoyama A (September 2013).
"Differences by sex in the prevalence of diabetes mellitus, impaired fasting glycaemia and impaired glucose tolerance in sub-Saharan Africa: a systematic review and meta-analysis"
.
Bulletin of the World Health Organization
.
91
(9): 671?682D.
doi
:
10.2471/BLT.12.113415
.
PMC
3790213
.
PMID
24101783
.
- ^
Christian P, Stewart CP (March 2010).
"Maternal micronutrient deficiency, fetal development, and the risk of chronic disease"
.
The Journal of Nutrition
.
140
(3): 437?45.
doi
:
10.3945/jn.109.116327
.
PMID
20071652
.
- ^
Pedersen HK, Gudmundsdottir V, Nielsen HB, Hyotylainen T, Nielsen T, Jensen BA, et al. (July 2016).
"Human gut microbes impact host serum metabolome and insulin sensitivity"
.
Nature
.
535
(7612): 376?81.
Bibcode
:
2016Natur.535..376P
.
doi
:
10.1038/nature18646
.
PMID
27409811
.
S2CID
4459808
.
[
permanent dead link
]
- ^
Abdullah A, Peeters A, de Courten M, Stoelwinder J (September 2010). "The magnitude of association between overweight and obesity and the risk of diabetes: a meta-analysis of prospective cohort studies".
Diabetes Research and Clinical Practice
.
89
(3): 309?19.
doi
:
10.1016/j.diabres.2010.04.012
.
PMID
20493574
.
- ^
Pan A, Wang Y, Talaei M, Hu FB, Wu T (December 2015).
"Relation of active, passive, and quitting smoking with incident type 2 diabetes: a systematic review and meta-analysis"
.
The Lancet. Diabetes & Endocrinology
.
3
(12): 958?67.
doi
:
10.1016/S2213-8587(15)00316-2
.
PMC
4656094
.
PMID
26388413
.
- ^
a
b
Touma C, Pannain S (August 2011).
"Does lack of sleep cause diabetes?"
.
Cleveland Clinic Journal of Medicine
.
78
(8): 549?58.
doi
:
10.3949/ccjm.78a.10165
.
PMID
21807927
.
S2CID
45708828
.
- ^
Malik VS, Popkin BM, Bray GA, Despres JP, Hu FB (March 2010).
"Sugar-sweetened beverages, obesity, type 2 diabetes mellitus, and cardiovascular disease risk"
.
Circulation
.
121
(11): 1356?64.
doi
:
10.1161/CIRCULATIONAHA.109.876185
.
PMC
2862465
.
PMID
20308626
.
- ^
Malik VS, Popkin BM, Bray GA, Despres JP, Willett WC, Hu FB (November 2010).
"Sugar-sweetened beverages and risk of metabolic syndrome and type 2 diabetes: a meta-analysis"
.
Diabetes Care
.
33
(11): 2477?83.
doi
:
10.2337/dc10-1079
.
PMC
2963518
.
PMID
20693348
.
- ^
Hu EA, Pan A, Malik V, Sun Q (March 2012).
"White rice consumption and risk of type 2 diabetes: meta-analysis and systematic review"
.
BMJ
.
344
: e1454.
doi
:
10.1136/bmj.e1454
.
PMC
3307808
.
PMID
22422870
.
- ^
Lee IM, Shiroma EJ, Lobelo F, Puska P, Blair SN, Katzmarzyk PT (July 2012).
"Effect of physical inactivity on major non-communicable diseases worldwide: an analysis of burden of disease and life expectancy"
.
Lancet
.
380
(9838): 219?29.
doi
:
10.1016/S0140-6736(12)61031-9
.
PMC
3645500
.
PMID
22818936
.
- ^
Lind L, Lind PM (June 2012).
"Can persistent organic pollutants and plastic-associated chemicals cause cardiovascular disease?"
.
Journal of Internal Medicine
.
271
(6): 537?53.
doi
:
10.1111/j.1365-2796.2012.02536.x
.
PMID
22372998
.
S2CID
41018361
.
- ^
Willemsen G, Ward KJ, Bell CG, Christensen K, Bowden J, Dalgard C, et al. (December 2015).
"The Concordance and Heritability of Type 2 Diabetes in 34,166 Twin Pairs From International Twin Registers: The Discordant Twin (DISCOTWIN) Consortium"
.
Twin Research and Human Genetics
.
18
(6): 762?771.
doi
:
10.1017/thg.2015.83
.
PMID
26678054
.
- ^
a
b
Herder C, Roden M (June 2011).
"Genetics of type 2 diabetes: pathophysiologic and clinical relevance"
.
European Journal of Clinical Investigation
.
41
(6): 679?692.
doi
:
10.1111/j.1365-2362.2010.02454.x
.
PMID
21198561
.
S2CID
43548816
.
- ^
Fuchsberger C, Flannick J, Teslovich TM, Mahajan A, Agarwala V, Gaulton KJ, et al. (August 2016).
"The genetic architecture of type 2 diabetes"
.
Nature
.
536
(7614): 41?47.
Bibcode
:
2016Natur.536...41F
.
doi
:
10.1038/nature18642
.
PMC
5034897
.
PMID
27398621
.
- ^
"Monogenic Forms of Diabetes: Neonatal Diabetes Mellitus and Maturity-onset Diabetes of the Young"
.
National Diabetes Information Clearinghouse (NDIC)
. National Institute of Diabetes and Digestive and Kidney Diseases, NIH. March 2007.
Archived
from the original on 2008-07-04
. Retrieved
2008-08-04
.
- ^
Rosen ED, Kaestner KH, Natarajan R, Patti ME, Sallari R, Sander M, Susztak K. Epigenetics and Epigenomics: Implications for Diabetes and Obesity. Diabetes. 2018 Oct;67(10):1923-1931. doi: 10.2337/db18-0537. PMID 30237160; PMCID: PMC6463748
- ^
a
b
Funnell MM, Anderson RM (2008).
"Influencing self-management: from compliance to collaboration"
. In Bethel MN, Feinglos MA (eds.).
Type 2 diabetes mellitus: an evidence-based approach to practical management
. Contemporary endocrinology. Totowa, NJ: Humana Press. p. 462.
ISBN
978-1-58829-794-5
.
OCLC
261324723
.
- ^
Izzedine H, Launay-Vacher V, Deybach C, Bourry E, Barrou B, Deray G (November 2005). "Drug-induced diabetes mellitus".
Expert Opinion on Drug Safety
.
4
(6): 1097?1109.
doi
:
10.1517/14740338.4.6.1097
.
PMID
16255667
.
S2CID
21532595
.
- ^
Sampson UK, Linton MF, Fazio S (July 2011).
"Are statins diabetogenic?"
.
Current Opinion in Cardiology
.
26
(4): 342?347.
doi
:
10.1097/HCO.0b013e3283470359
.
PMC
3341610
.
PMID
21499090
.
- ^
Giovannucci E, Harlan DM, Archer MC, Bergenstal RM, Gapstur SM, Habel LA, et al. (July 2010).
"Diabetes and cancer: a consensus report"
.
Diabetes Care
(Professional society guidelines).
33
(7): 1674?1685.
doi
:
10.2337/dc10-0666
.
PMC
2890380
.
PMID
20587728
.
- ^
Saad F, Gooren L (March 2009). "The role of testosterone in the metabolic syndrome: a review".
The Journal of Steroid Biochemistry and Molecular Biology
.
114
(1?2): 40?43.
doi
:
10.1016/j.jsbmb.2008.12.022
.
PMID
19444934
.
S2CID
22222112
.
- ^
Farrell JB, Deshmukh A, Baghaie AA (2008).
"Low testosterone and the association with type 2 diabetes"
.
The Diabetes Educator
.
34
(5): 799?806.
doi
:
10.1177/0145721708323100
.
PMID
18832284
.
- ^
Nieto-Martinez R, Gonzalez-Rivas JP, Medina-Inojosa JR, Florez H (November 2017). "Are Eating Disorders Risk Factors for Type 2 Diabetes? A Systematic Review and Meta-analysis".
Current Diabetes Reports
(Systematic review and meta-analysis).
17
(12): 138.
doi
:
10.1007/s11892-017-0949-1
.
PMID
29168047
.
S2CID
3688434
.
- ^
Cobelli C, Toffolo GM, Dalla Man C, Campioni M, Denti P, Caumo A, et al. (July 2007). "Assessment of beta-cell function in humans, simultaneously with insulin sensitivity and hepatic extraction, from intravenous and oral glucose tests".
American Journal of Physiology. Endocrinology and Metabolism
.
293
(1): E1?E15.
doi
:
10.1152/ajpendo.00421.2006
.
PMID
17341552
.
- ^
Hannon TS,
Kahn SE
, Utzschneider KM, Buchanan TA, Nadeau KJ, Zeitler PS, et al. (January 2018).
"Review of methods for measuring β-cell function: Design considerations from the Restoring Insulin Secretion (RISE) Consortium"
.
Diabetes, Obesity & Metabolism
.
20
(1): 14?24.
doi
:
10.1111/dom.13005
.
PMC
6095472
.
PMID
28493515
.
- ^
Dietrich JW, Abood A, Dasgupta R, Anoop S, Jebasingh FK, Spurgeon R, et al. (2 January 2024).
"A novel simple disposition index (SPINA-DI) from fasting insulin and glucose concentration as a robust measure of carbohydrate homeostasis"
.
Journal of Diabetes
.
doi
:
10.1111/1753-0407.13525
.
PMID
38169110
.
- ^
Diabetes mellitus a guide to patient care
. Philadelphia: Lippincott Williams & Wilkins. 2007. p.
15
.
ISBN
978-1-58255-732-8
.
- ^
a
b
c
Sun T, Han X (2019). "Death versus dedifferentiation: The molecular bases of beta cell mass reduction in type 2 diabetes".
Seminars in Cell and Developmental Biology
.
103
: 76?82.
doi
:
10.1016/j.semcdb.2019.12.002
.
PMID
31831356
.
S2CID
209341381
.
- ^
Reed J, Bain S, Kanamarlapudi V (August 2021).
"A Review of Current Trends with Type 2 Diabetes Epidemiology, Aetiology, Pathogenesis, Treatments and Future Perspectives"
.
Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy
.
14
: 3567?3602.
doi
:
10.2147/DMSO.S319895
.
PMC
8369920
.
PMID
34413662
.
- ^
Schriever SC, Kabra DG, Pfuhlmann K, Baumann P, Baumgart EV, Nagler J, et al. (November 2020).
"Type 2 diabetes risk gene Dusp8 regulates hypothalamic Jnk signaling and insulin sensitivity"
.
The Journal of Clinical Investigation
.
130
(11): 6093?6108.
doi
:
10.1172/JCI136363
.
PMC
7598066
.
PMID
32780722
.
- ^
German JP, Wisse BE, Thaler JP, Oh-I S, Sarruf DA, Ogimoto K, et al. (July 2010).
"Leptin deficiency causes insulin resistance induced by uncontrolled diabetes"
.
Diabetes
.
59
(7): 1626?1634.
doi
:
10.2337/db09-1918
.
PMC
2889761
.
PMID
20424233
.
- ^
Lundqvist MH, Almby K, Wiklund U, Abrahamsson N, Kamble PG, Pereira MJ, et al. (March 2021).
"Altered hormonal and autonomic nerve responses to hypo- and hyperglycaemia are found in overweight and insulin-resistant individuals and may contribute to the development of type 2 diabetes"
.
Diabetologia
.
64
(3): 641?655.
doi
:
10.1007/s00125-020-05332-z
.
PMC
7864814
.
PMID
33241460
.
- ^
Salazar J, Chavez-Castillo M, Rojas J, Ortega A, Nava M, Perez J, et al. (2020-07-23). "Is "Leptin Resistance" Another Key Resistance to Manage Type 2 Diabetes?".
Current Diabetes Reviews
.
16
(7): 733?749.
doi
:
10.2174/1573399816666191230111838
.
PMID
31886750
.
S2CID
209510992
.
- ^
Alonge KM, D'Alessio DA, Schwartz MW (January 2021).
"Brain control of blood glucose levels: implications for the pathogenesis of type 2 diabetes"
.
Diabetologia
.
64
(1): 5?14.
doi
:
10.1007/s00125-020-05293-3
.
PMC
7718404
.
PMID
33043401
.
- ^
Bentsen MA, Rausch DM, Mirzadeh Z, Muta K, Scarlett JM, Brown JM, et al. (September 2020).
"Transcriptomic analysis links diverse hypothalamic cell types to fibroblast growth factor 1-induced sustained diabetes remission"
.
Nature Communications
.
11
(1): 4458.
Bibcode
:
2020NatCo..11.4458B
.
doi
:
10.1038/s41467-020-17720-5
.
PMC
7477234
.
PMID
32895383
.
- ^
Adlanmerini M, Nguyen HC, Krusen BM, Teng CW, Geisler CE, Peed LC, et al. (January 2021).
"Hypothalamic REV-ERB nuclear receptors control diurnal food intake and leptin sensitivity in diet-induced obese mice"
.
The Journal of Clinical Investigation
.
131
(1): e140424.
doi
:
10.1172/JCI140424
.
PMC
7773391
.
PMID
33021965
.
- ^
Yasumoto Y, Miyazaki H, Ogata M, Kagawa Y, Yamamoto Y, Islam A, et al. (December 2018). "Glial Fatty Acid-Binding Protein 7 (FABP7) Regulates Neuronal Leptin Sensitivity in the Hypothalamic Arcuate Nucleus".
Molecular Neurobiology
.
55
(12): 9016?9028.
doi
:
10.1007/s12035-018-1033-9
.
PMID
29623545
.
S2CID
4632807
.
- ^
Young JK, Baker JH, Muller T (March 1996). "Immunoreactivity for brain-fatty acid binding protein in gomori-positive astrocytes".
Glia
.
16
(3): 218?226.
doi
:
10.1002/(SICI)1098-1136(199603)16:3<218::AID-GLIA4>3.0.CO;2-Y
.
PMID
8833192
.
S2CID
9757285
.
- ^
Schmidt SP, Corydon TJ, Pedersen CB, Vang S, Palmfeldt J, Stenbroen V, et al. (April 2011).
"Toxic response caused by a misfolding variant of the mitochondrial protein short-chain acyl-CoA dehydrogenase"
.
Journal of Inherited Metabolic Disease
.
34
(2): 465?475.
doi
:
10.1007/s10545-010-9255-7
.
PMC
3063561
.
PMID
21170680
.
- ^
Definition and diagnosis of diabetes mellitus and intermediate hyperglycemia: Report of a WHO/IDF consultation
(PDF)
. Geneva:
World Health Organization
. 2006. p. 21.
ISBN
978-92-4-159493-6
.
- ^
Vijan S (March 2010). "In the clinic. Type 2 diabetes".
Annals of Internal Medicine
.
152
(5): ITC31-15, quiz ITC316.
doi
:
10.7326/0003-4819-152-5-201003020-01003
.
PMID
20194231
.
- ^
World Health Organization.
"Definition, diagnosis and classification of diabetes mellitus and its complications: Report of a WHO Consultation. Part 1. Diagnosis and classification of diabetes mellitus"
. Archived from
the original
on 2007-05-29
. Retrieved
2007-05-29
.
- ^
a
b
c
International Expert Committee (July 2009).
"International Expert Committee report on the role of the A1C assay in the diagnosis of diabetes"
.
Diabetes Care
.
32
(7): 1327?34.
doi
:
10.2337/dc09-9033
.
PMC
2699715
.
PMID
19502545
.
- ^
American Diabetes Association (January 2010).
"Diagnosis and classification of diabetes mellitus"
.
Diabetes Care
.
33
(Supplement_1): S62-9.
doi
:
10.2337/dc10-S062
.
PMC
2797383
.
PMID
20042775
.
- ^
a
b
c
d
e
f
g
Fox CS, Golden SH, Anderson C, Bray GA, Burke LE, de Boer IH, et al. (September 2015).
"Update on Prevention of Cardiovascular Disease in Adults With Type 2 Diabetes Mellitus in Light of Recent Evidence: A Scientific Statement From the American Heart Association and the American Diabetes Association"
.
Diabetes Care
(Professional society guidelines).
38
(9): 1777?1803.
doi
:
10.2337/dci15-0012
.
PMC
4876675
.
PMID
26246459
.
- ^
American Diabetes Association (January 2012).
"Diagnosis and classification of diabetes mellitus"
.
Diabetes Care
.
35
(Suppl 1): S64-71.
doi
:
10.2337/dc12-s064
.
PMC
3632174
.
PMID
22187472
.
- ^
Kumar V, Fausto N, Abbas AK, Cotran RS, Robbins SL (2005).
Robbins and Cotran Pathologic Basis of Disease
(7th ed.). Philadelphia, Pa.: Saunders. pp. 1194?95.
ISBN
978-0-7216-0187-8
.
- ^
Diabetes mellitus a guide to patient care
. Philadelphia: Lippincott Williams & Wilkins. 2007. p.
201
.
ISBN
978-1-58255-732-8
.
- ^
Vivian EM, Blackorbay B (2013).
"Chapter 13: Endocrine Disorders"
. In Lee M (ed.).
Basic Skills in Interpreting Laboratory Data
(5th ed.). Bethesda, MD: American Society of Health-System Pharmacists.
ISBN
978-1-58528-345-3
.
OCLC
859778842
.
- ^
Valdez R (July 2009).
"Detecting undiagnosed type 2 diabetes: family history as a risk factor and screening tool"
.
Journal of Diabetes Science and Technology
.
3
(4): 722?6.
doi
:
10.1177/193229680900300417
.
PMC
2769984
.
PMID
20144319
.
- ^
a
b
Selph S, Dana T, Blazina I, Bougatsos C, Patel H, Chou R (June 2015).
"Screening for type 2 diabetes mellitus: a systematic review for the U.S. Preventive Services Task Force"
.
Annals of Internal Medicine
.
162
(11): 765?76.
doi
:
10.7326/M14-2221
.
PMID
25867111
.
- ^
a
b
"Recommendation: Prediabetes and Type 2 Diabetes: Screening | United States Preventive Services Taskforce"
.
www.uspreventiveservicestaskforce.org
. Retrieved
2023-01-13
.
- ^
Siu AL (December 2015).
"Screening for Abnormal Blood Glucose and Type 2 Diabetes Mellitus: U.S. Preventive Services Task Force Recommendation Statement"
.
Annals of Internal Medicine
.
163
(11): 861?8.
doi
:
10.7326/M15-2345
.
PMID
26501513
.
- ^
a
b
c
d
"Standards of medical care in diabetes--2015: summary of revisions"
.
Diabetes Care
.
38
(38): S4. January 2015.
doi
:
10.2337/dc15-S003
.
PMID
25537706
.
- ^
a
b
"Archived: Diabetes Mellitus (Type 2) in Adults: Screening"
.
U.S. Preventive Services Task Force
. June 2008.
Archived
from the original on 2014-02-07
. Retrieved
2014-03-16
.
- ^
Peer N, Balakrishna Y, Durao S (May 2020).
"Screening for type 2 diabetes mellitus"
.
The Cochrane Database of Systematic Reviews
.
5
(6): CD005266.
doi
:
10.1002/14651858.cd005266.pub2
.
PMC
7259754
.
PMID
32470201
.
- ^
a
b
"Diabetes: putting people at the heart of services"
.
NIHR Evidence
. National Institute for Health and Care Research. 2022-07-26.
doi
:
10.3310/nihrevidence_52026
.
S2CID
251299176
.
- ^
"Are you at risk of diabetes? Research finds prevention should start at a different BMI for each ethnic group"
.
NIHR Evidence
(Plain English summary). National Institute for Health and Care Research. 2022-03-10.
doi
:
10.3310/alert_48878
.
S2CID
247390548
.
- ^
Caleyachetty R, Barber TM, Mohammed NI, Cappuccio FP, Hardy R, Mathur R, et al. (July 2021).
"Ethnicity-specific BMI cutoffs for obesity based on type 2 diabetes risk in England: a population-based cohort study"
.
The Lancet. Diabetes & Endocrinology
.
9
(7): 419?426.
doi
:
10.1016/S2213-8587(21)00088-7
.
PMC
8208895
.
PMID
33989535
.
- ^
Raina Elley C, Kenealy T (December 2008). "Lifestyle interventions reduced the long-term risk of diabetes in adults with impaired glucose tolerance".
Evidence-Based Medicine
.
13
(6): 173.
doi
:
10.1136/ebm.13.6.173
.
PMID
19043031
.
S2CID
26714233
.
- ^
Hemmingsen B, Gimenez-Perez G, Mauricio D, Roque I, Figuls M, Metzendorf MI, et al. (December 2017).
"Diet, physical activity or both for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk of developing type 2 diabetes mellitus"
.
The Cochrane Database of Systematic Reviews
.
2017
(12): CD003054.
doi
:
10.1002/14651858.CD003054.pub4
.
PMC
6486271
.
PMID
29205264
.
- ^
a
b
Schellenberg ES, Dryden DM, Vandermeer B, Ha C, Korownyk C (October 2013).
"Lifestyle interventions for patients with and at risk for type 2 diabetes: a systematic review and meta-analysis"
.
Annals of Internal Medicine
.
159
(8): 543?551.
doi
:
10.7326/0003-4819-159-8-201310150-00007
.
PMID
24126648
.
- ^
O'Gorman DJ, Krook A (September 2011). "Exercise and the treatment of diabetes and obesity".
The Medical Clinics of North America
.
95
(5): 953?969.
doi
:
10.1016/j.mcna.2011.06.007
.
PMID
21855702
.
- ^
Kyu HH, Bachman VF, Alexander LT, Mumford JE, Afshin A, Estep K, et al. (August 2016).
"Physical activity and risk of breast cancer, colon cancer, diabetes, ischemic heart disease, and ischemic stroke events: systematic review and dose-response meta-analysis for the Global Burden of Disease Study 2013"
.
BMJ
.
354
: i3857.
doi
:
10.1136/bmj.i3857
.
PMC
4979358
.
PMID
27510511
.
- ^
Nield L, Summerbell CD, Hooper L, Whittaker V, Moore H (July 2008). Nield L (ed.). "Dietary advice for the prevention of type 2 diabetes mellitus in adults".
The Cochrane Database of Systematic Reviews
(3): CD005102.
doi
:
10.1002/14651858.CD005102.pub2
.
hdl
:
10149/92337
.
PMID
18646120
.
S2CID
23039006
.
(Retracted)
- ^
Carter P, Gray LJ, Troughton J, Khunti K, Davies MJ (August 2010).
"Fruit and vegetable intake and incidence of type 2 diabetes mellitus: systematic review and meta-analysis"
.
BMJ
.
341
: c4229.
doi
:
10.1136/bmj.c4229
.
PMC
2924474
.
PMID
20724400
.
- ^
Schwingshackl L, Hoffmann G, Lampousi AM, Knuppel S, Iqbal K, Schwedhelm C, et al. (May 2017).
"Food groups and risk of type 2 diabetes mellitus: a systematic review and meta-analysis of prospective studies"
.
European Journal of Epidemiology
.
32
(5): 363?375.
doi
:
10.1007/s10654-017-0246-y
.
PMC
5506108
.
PMID
28397016
.
- ^
Xi B, Li S, Liu Z, Tian H, Yin X, Huai P, et al. (2014).
"Intake of fruit juice and incidence of type 2 diabetes: a systematic review and meta-analysis"
.
PLOS ONE
.
9
(3): e93471.
Bibcode
:
2014PLoSO...993471X
.
doi
:
10.1371/journal.pone.0093471
.
PMC
3969361
.
PMID
24682091
.
- ^
Reynolds A, Mann J, Cummings J, Winter N, Mete E, Te Morenga L (February 2019).
"Carbohydrate quality and human health: a series of systematic reviews and meta-analyses"
.
Lancet
.
393
(10170): 434?445.
doi
:
10.1016/S0140-6736(18)31809-9
.
PMID
30638909
.
S2CID
58632705
.
- ^
a
b
c
Madsen KS, Chi Y, Metzendorf MI, Richter B, Hemmingsen B, et al. (Cochrane Metabolic and Endocrine Disorders Group) (December 2019).
"Metformin for prevention or delay of type 2 diabetes mellitus and its associated complications in persons at increased risk for the development of type 2 diabetes mellitus"
.
The Cochrane Database of Systematic Reviews
.
2019
(12): CD008558.
doi
:
10.1002/14651858.CD008558.pub2
.
PMC
6889926
.
PMID
31794067
.
- ^
a
b
c
Moelands SV, Lucassen PL, Akkermans RP, De Grauw WJ, Van de Laar FA (2018-12-28). Cochrane Metabolic and Endocrine Disorders Group (ed.).
"Alpha-glucosidase inhibitors for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk of developing type 2 diabetes mellitus"
.
Cochrane Database of Systematic Reviews
.
2018
(12): CD005061.
doi
:
10.1002/14651858.CD005061.pub3
.
PMC
6517235
.
PMID
30592787
.
- ^
Haw JS, Galaviz KI, Straus AN, Kowalski AJ, Magee MJ, Weber MB, et al. (December 2017).
"Long-term Sustainability of Diabetes Prevention Approaches: A Systematic Review and Meta-analysis of Randomized Clinical Trials"
.
JAMA Internal Medicine
.
177
(12): 1808?1817.
doi
:
10.1001/jamainternmed.2017.6040
.
PMC
5820728
.
PMID
29114778
.
- ^
Seida JC, Mitri J, Colmers IN, Majumdar SR, Davidson MB, Edwards AL, et al. (October 2014).
"Clinical review: Effect of vitamin D3 supplementation on improving glucose homeostasis and preventing diabetes: a systematic review and meta-analysis"
.
The Journal of Clinical Endocrinology and Metabolism
.
99
(10): 3551?60.
doi
:
10.1210/jc.2014-2136
.
PMC
4483466
.
PMID
25062463
.
- ^
Mannucci E, Giaccari A, Gallo M, Bonifazi A, Belen AD, Masini ML, et al. (February 2022). "Self-management in patients with type 2 diabetes: Group-based versus individual education. A systematic review with meta-analysis of randomized trails".
Nutrition, Metabolism, and Cardiovascular Diseases
.
32
(2): 330?336.
doi
:
10.1016/j.numecd.2021.10.005
.
PMID
34893413
.
S2CID
244580173
.
- ^
"Type 2 diabetes: The management of type 2 diabetes"
. May 2009.
Archived
from the original on 2015-05-22.
- ^
Emdin CA, Rahimi K, Neal B, Callender T, Perkovic V, Patel A (February 2015).
"Blood pressure lowering in type 2 diabetes: a systematic review and meta-analysis"
.
JAMA
.
313
(6): 603?615.
doi
:
10.1001/jama.2014.18574
.
PMID
25668264
.
- ^
McBrien K, Rabi DM, Campbell N, Barnieh L, Clement F, Hemmelgarn BR, et al. (September 2012).
"Intensive and Standard Blood Pressure Targets in Patients With Type 2 Diabetes Mellitus: Systematic Review and Meta-analysis"
.
Archives of Internal Medicine
.
172
(17): 1296?1303.
doi
:
10.1001/archinternmed.2012.3147
.
PMID
22868819
.
- ^
Boussageon R, Bejan-Angoulvant T, Saadatian-Elahi M, Lafont S, Bergeonneau C, Kassai B, et al. (July 2011).
"Effect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: meta-analysis of randomised controlled trials"
.
BMJ
.
343
: d4169.
doi
:
10.1136/bmj.d4169
.
PMC
3144314
.
PMID
21791495
.
- ^
Webster MW (July 2011). "Clinical practice and implications of recent diabetes trials".
Current Opinion in Cardiology
.
26
(4): 288?93.
doi
:
10.1097/HCO.0b013e328347b139
.
PMID
21577100
.
S2CID
20819316
.
- ^
a
b
c
Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, et al. (March 2015).
"Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. Update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes"
.
Diabetologia
.
58
(3): 429?42.
doi
:
10.1007/s00125-014-3460-0
.
PMID
25583541
.
- ^
Qaseem A, Wilt TJ, Kansagara D, Horwitch C, Barry MJ, Forciea MA (April 2018).
"Hemoglobin A1c Targets for Glycemic Control With Pharmacologic Therapy for Nonpregnant Adults With Type 2 Diabetes Mellitus: A Guidance Statement Update From the American College of Physicians"
.
Annals of Internal Medicine
.
168
(8): 569?576.
doi
:
10.7326/M17-0939
.
PMID
29507945
.
- ^
Seaquist ER, Anderson J, Childs B, Cryer P, Dagogo-Jack S, Fish L, et al. (May 2013).
"Hypoglycemia and diabetes: a report of a workgroup of the American Diabetes Association and the Endocrine Society"
.
Diabetes Care
(Professional society guidelines).
36
(5): 1384?1395.
doi
:
10.2337/dc12-2480
.
PMC
3631867
.
PMID
23589542
.
- ^
Makam AN, Nguyen OK (January 2017).
"An Evidence-Based Medicine Approach to Antihyperglycemic Therapy in Diabetes Mellitus to Overcome Overtreatment"
.
Circulation
.
135
(2): 180?195.
doi
:
10.1161/CIRCULATIONAHA.116.022622
.
PMC
5502688
.
PMID
28069712
.
- ^
Simpson TC, Clarkson JE, Worthington HV, MacDonald L, Weldon JC, Needleman I, et al. (April 14, 2022).
"Treatment of periodontitis for glycaemic control in people with diabetes mellitus"
.
The Cochrane Database of Systematic Reviews
.
2022
(4): CD004714.
doi
:
10.1002/14651858.CD004714.pub4
.
hdl
:
2164/20480
.
PMC
9009294
.
PMID
35420698
.
- ^
Smith AD, Crippa A, Woodcock J, Brage S (December 2016).
"Physical activity and incident type 2 diabetes mellitus: a systematic review and dose-response meta-analysis of prospective cohort studies"
.
Diabetologia
.
59
(12): 2527?2545.
doi
:
10.1007/s00125-016-4079-0
.
PMC
6207340
.
PMID
27747395
.
- ^
Thomas DE, Elliott EJ, Naughton GA (July 2006).
"Exercise for type 2 diabetes mellitus"
.
The Cochrane Database of Systematic Reviews
.
2009
(3): CD002968.
doi
:
10.1002/14651858.CD002968.pub2
.
PMC
8989410
.
PMID
16855995
.
S2CID
25505640
.
- ^
Davis N, Forbes B, Wylie-Rosett J (June 2009). "Nutritional strategies in type 2 diabetes mellitus".
The Mount Sinai Journal of Medicine, New York
.
76
(3): 257?268.
doi
:
10.1002/msj.20118
.
PMID
19421969
.
- ^
Magkos F, Hjorth MF, Astrup A (October 2020).
"Diet and exercise in the prevention and treatment of type 2 diabetes mellitus"
.
Nature Reviews Endocrinology
.
16
(10): 545?555.
doi
:
10.1038/s41574-020-0381-5
.
ISSN
1759-5037
.
PMID
32690918
.
S2CID
220651657
.
A weight loss of ~15?kg, achieved by calorie restriction as part of an intensive management programme, can lead to remission of T2DM in ~80% of patients with obesity and T2DM.
- ^
"Achieving Type 2 Diabetes Remission through Weight Loss"
.
National Institute of Diabetes and Digestive and Kidney Diseases
. 30 September 2020
. Retrieved
29 November
2023
.
- ^
a
b
"Initial management of hyperglycemia in adults with type 2 diabetes mellitus"
.
UpToDate
. September 2023
. Retrieved
29 November
2023
.
- ^
American Diabetes Association (1 January 2021).
"8. Obesity Management for the Treatment of Type 2 Diabetes: Standards of Medical Care in Diabetes?2021"
.
Diabetes Care
.
44
(Supplement_1): S100?S110.
doi
:
10.2337/dc21-S008
.
PMID
33298419
.
S2CID
228087486
.
- ^
Thomas D, Elliott EJ (January 2009). Thomas D (ed.).
"Low glycaemic index, or low glycaemic load, diets for diabetes mellitus"
.
The Cochrane Database of Systematic Reviews
.
2009
(1): CD006296.
doi
:
10.1002/14651858.CD006296.pub2
.
PMC
6486008
.
PMID
19160276
.
- ^
Feinman RD, Pogozelski WK, Astrup A, Bernstein RK, Fine EJ, Westman EC, et al. (January 2015).
"Dietary carbohydrate restriction as the first approach in diabetes management: critical review and evidence base"
.
Nutrition
.
31
(1): 1?13.
doi
:
10.1016/j.nut.2014.06.011
.
PMID
25287761
.
- ^
Evert AB, Boucher JL, Cypress M, Dunbar SA, Franz MJ, Mayer-Davis EJ, et al. (January 2014).
"Nutrition therapy recommendations for the management of adults with diabetes"
.
Diabetes Care
(Professional society guidelines).
37
(Supplement_1): S120?S143.
doi
:
10.2337/dc14-S120
.
PMID
24357208
.
- ^
Muley A, Fernandez R, Ellwood L, Muley P, Shah M (May 2021). "Effect of tree nuts on glycemic outcomes in adults with type 2 diabetes mellitus: a systematic review".
JBI Evidence Synthesis
.
19
(5): 966?1002.
doi
:
10.11124/JBISRIR-D-19-00397
.
PMID
33141798
.
S2CID
226250006
.
- ^
Gardner C, Wylie-Rosett J, Gidding SS, Steffen LM, Johnson RK, Reader D, et al. (August 2012).
"Nonnutritive sweeteners: current use and health perspectives: a scientific statement from the American Heart Association and the American Diabetes Association"
.
Diabetes Care
.
35
(8): 1798?1808.
doi
:
10.2337/dc12-9002
.
PMC
3402256
.
PMID
22778165
.
- ^
Xu B, Fu J, Qiao Y, Cao J, Deehan EC, Li Z, et al. (June 2021).
"Higher intake of microbiota-accessible carbohydrates and improved cardiometabolic risk factors: a meta-analysis and umbrella review of dietary management in patients with type 2 diabetes"
.
The American Journal of Clinical Nutrition
.
113
(6): 1515?1530.
doi
:
10.1093/ajcn/nqaa435
.
PMID
33693499
.
- ^
Jovanovski E, Khayyat R, Zurbau A, Komishon A, Mazhar N, Sievenpiper JL, et al. (May 2019).
"Should Viscous Fiber Supplements Be Considered in Diabetes Control? Results From a Systematic Review and Meta-analysis of Randomized Controlled Trials"
.
Diabetes Care
.
42
(5): 755?766.
doi
:
10.2337/dc18-1126
.
PMID
30617143
.
S2CID
58665219
.
- ^
Attridge M, Creamer J, Ramsden M, Cannings-John R, Hawthorne K (September 2014).
"Culturally appropriate health education for people in ethnic minority groups with type 2 diabetes mellitus"
.
The Cochrane Database of Systematic Reviews
.
2014
(9): CD006424.
doi
:
10.1002/14651858.CD006424.pub3
.
PMC
10680058
.
PMID
25188210
.
- ^
Hackett RA, Steptoe A (2017).
"Type 2 diabetes mellitus and psychological stress ? a modifiable risk factor"
.
Nature Reviews Endocrinology
.
13
(9): 547?560.
doi
:
10.1038/nrendo.2017.64
.
ISSN
1759-5029
.
PMID
28664919
.
S2CID
34925223
.
- ^
Ee CC, Armour M, Piya MK, McMorrow R, Al-Kanini I, Sabag A (2021-12-23). Cochrane Metabolic and Endocrine Disorders Group (ed.).
"Mindfulness-based interventions for adults with type 2 diabetes mellitus"
.
Cochrane Database of Systematic Reviews
.
2021
(12): CD014881.
doi
:
10.1002/14651858.CD014881
.
PMC
8701561
.
- ^
Palmer SC, Mavridis D, Nicolucci A, Johnson DW, Tonelli M, Craig JC, et al. (July 2016).
"Comparison of Clinical Outcomes and Adverse Events Associated With Glucose-Lowering Drugs in Patients With Type 2 Diabetes: A Meta-analysis"
.
JAMA
.
316
(3): 313?24.
doi
:
10.1001/jama.2016.9400
.
PMID
27434443
.
- ^
Boussageon R, Supper I, Bejan-Angoulvant T, Kellou N, Cucherat M, Boissel JP, et al. (2012). Groop L (ed.).
"Reappraisal of metformin efficacy in the treatment of type 2 diabetes: a meta-analysis of randomised controlled trials"
.
PLOS Medicine
.
9
(4): e1001204.
doi
:
10.1371/journal.pmed.1001204
.
PMC
3323508
.
PMID
22509138
.
- ^
Marx N, Davies MJ, Grant PJ, Mathieu C, Petrie JR, Cosentino F, et al. (January 2021).
"Guideline recommendations and the positioning of newer drugs in type 2 diabetes care"
.
The Lancet Diabetes & Endocrinology
.
9
(1): 46?52.
doi
:
10.1016/S2213-8587(20)30343-0
.
PMID
33159841
.
S2CID
226280186
.
- ^
American Diabetes Association Professional Practice Committee (January 2022).
"9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes-2022"
.
Diabetes Care
.
45
(Suppl 1): S125?S143.
doi
:
10.2337/dc22-S009
.
PMID
34964831
.
S2CID
245538347
.
- ^
Choi JG, Winn AN, Skandari MR, Franco MI, Staab EM, Alexander J, et al. (October 2022).
"First-Line Therapy for Type 2 Diabetes With Sodium-Glucose Cotransporter-2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists : A Cost-Effectiveness Study"
.
Annals of Internal Medicine
.
175
(10): 1392?1400.
doi
:
10.7326/M21-2941
.
ISSN
1539-3704
.
PMC
10155215
.
PMID
36191315
.
- ^
Baker C, Retzik-Stahr C, Singh V, Plomondon R, Anderson V, Rasouli N (13 January 2021).
"Should metformin remain the first-line therapy for treatment of type 2 diabetes?"
.
Therapeutic Advances in Endocrinology and Metabolism
.
12
: 2042018820980225.
doi
:
10.1177/2042018820980225
.
ISSN
2042-0188
.
PMC
7809522
.
PMID
33489086
.
- ^
Zheng SL, Roddick AJ, Aghar-Jaffar R, Shun-Shin MJ, Francis D, Oliver N, et al. (April 2018).
"Association Between Use of Sodium-Glucose Cotransporter 2 Inhibitors, Glucagon-like Peptide 1 Agonists, and Dipeptidyl Peptidase 4 Inhibitors With All-Cause Mortality in Patients With Type 2 Diabetes: A Systematic Review and Meta-analysis"
.
JAMA
.
319
(15): 1580?1591.
doi
:
10.1001/jama.2018.3024
.
PMC
5933330
.
PMID
29677303
.
- ^
Richter B, Bandeira-Echtler E, Bergerhoff K, Clar C, Ebrahim SH (July 2007). Richter B (ed.).
"Rosiglitazone for type 2 diabetes mellitus"
(PDF)
.
The Cochrane Database of Systematic Reviews
.
2007
(3): CD006063.
doi
:
10.1002/14651858.CD006063.pub2
.
PMC
7389529
.
PMID
17636824
.
- ^
Chen X, Yang L, Zhai SD (December 2012). "Risk of cardiovascular disease and all-cause mortality among diabetic patients prescribed rosiglitazone or pioglitazone: a meta-analysis of retrospective cohort studies".
Chinese Medical Journal
.
125
(23): 4301?6.
PMID
23217404
.
- ^
Swinnen SG, Simon AC, Holleman F, Hoekstra JB, Devries JH (July 2011). Simon AC (ed.).
"Insulin detemir versus insulin glargine for type 2 diabetes mellitus"
.
The Cochrane Database of Systematic Reviews
.
2011
(7): CD006383.
doi
:
10.1002/14651858.CD006383.pub2
.
PMC
6486036
.
PMID
21735405
.
- ^
Waugh N, Cummins E, Royle P, Clar C, Marien M, Richter B, et al. (July 2010).
"Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation"
.
Health Technology Assessment
.
14
(36): 1?248.
doi
:
10.3310/hta14360
.
PMID
20646668
.
- ^
Mitchell S, Malanda B, Damasceno A, Eckel RH, Gaita D, Kotseva K, et al. (September 2019).
"A Roadmap on the Prevention of Cardiovascular Disease Among People Living With Diabetes"
.
Global Heart
.
14
(3): 215?240.
doi
:
10.1016/j.gheart.2019.07.009
.
PMID
31451236
.
- ^
Brunstrom M, Carlberg B (February 2016).
"Effect of antihypertensive treatment at different blood pressure levels in patients with diabetes mellitus: systematic review and meta-analyses"
.
BMJ
.
352
: i717.
doi
:
10.1136/bmj.i717
.
PMC
4770818
.
PMID
26920333
.
- ^
Brunstrom M, Carlberg B (September 2019).
"Benefits and harms of lower blood pressure treatment targets: systematic review and meta-analysis of randomised placebo-controlled trials"
.
BMJ Open
.
9
(9): e026686.
doi
:
10.1136/bmjopen-2018-026686
.
PMC
6773352
.
PMID
31575567
.
- ^
Cheng J, Zhang W, Zhang X, Han F, Li X, He X, et al. (May 2014).
"Effect of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on all-cause mortality, cardiovascular deaths, and cardiovascular events in patients with diabetes mellitus: a meta-analysis"
.
JAMA Internal Medicine
.
174
(5): 773?785.
doi
:
10.1001/jamainternmed.2014.348
.
PMID
24687000
.
- ^
Zheng SL, Roddick AJ, Ayis S (September 2017).
"Effects of aliskiren on mortality, cardiovascular outcomes and adverse events in patients with diabetes and cardiovascular disease or risk: A systematic review and meta-analysis of 13,395 patients"
.
Diabetes & Vascular Disease Research
.
14
(5): 400?406.
doi
:
10.1177/1479164117715854
.
PMC
5600262
.
PMID
28844155
.
- ^
a
b
Catala-Lopez F, Macias Saint-Gerons D, Gonzalez-Bermejo D, Rosano GM,
Davis BR
, Ridao M, et al. (March 2016).
"Cardiovascular and Renal Outcomes of Renin-Angiotensin System Blockade in Adult Patients with Diabetes Mellitus: A Systematic Review with Network Meta-Analyses"
.
PLOS Medicine
.
13
(3): e1001971.
doi
:
10.1371/journal.pmed.1001971
.
PMC
4783064
.
PMID
26954482
.
- ^
Pignone M, Alberts MJ, Colwell JA, Cushman M, Inzucchi SE, Mukherjee D, et al. (June 2010).
"Aspirin for primary prevention of cardiovascular events in people with diabetes: a position statement of the American Diabetes Association, a scientific statement of the American Heart Association, and an expert consensus document of the American College of Cardiology Foundation"
.
Diabetes Care
.
33
(6): 1395?402.
doi
:
10.2337/dc10-0555
.
PMC
2875463
.
PMID
20508233
.
- ^
Mirhosseini N, Vatanparast H, Mazidi M, Kimball SM (September 2017).
"The Effect of Improved Serum 25-Hydroxyvitamin D Status on Glycemic Control in Diabetic Patients: A Meta-Analysis"
.
The Journal of Clinical Endocrinology and Metabolism
.
102
(9): 3097?3110.
doi
:
10.1210/jc.2017-01024
.
PMID
28957454
.
- ^
Neves AL, Freise L, Laranjo L, Carter AW, Darzi A, Mayer E (December 2020).
"Impact of providing patients access to electronic health records on quality and safety of care: a systematic review and meta-analysis"
.
BMJ Quality & Safety
.
29
(12): 1019?1032.
doi
:
10.1136/bmjqs-2019-010581
.
PMC
7785164
.
PMID
32532814
.
- ^
"Sharing electronic records with patients led to improved control of type two diabetes"
.
NIHR Evidence
(Plain English summary). 2020-10-21.
doi
:
10.3310/alert_42103
.
S2CID
242149388
.
- ^
Picot J, Jones J, Colquitt JL, Gospodarevskaya E, Loveman E, Baxter L, et al. (September 2009).
"The clinical effectiveness and cost-effectiveness of bariatric (weight loss) surgery for obesity: a systematic review and economic evaluation"
.
Health Technology Assessment
.
13
(41): 1?190, 215?357, iii?iv.
doi
:
10.3310/hta13410
.
hdl
:
10536/DRO/DU:30064294
.
PMID
19726018
.
- ^
Frachetti KJ, Goldfine AB (April 2009).
"Bariatric surgery for diabetes management"
.
Current Opinion in Endocrinology, Diabetes and Obesity
.
16
(2): 119?24.
doi
:
10.1097/MED.0b013e32832912e7
.
PMID
19276974
.
S2CID
31797748
.
- ^
a
b
Schulman AP, del Genio F, Sinha N, Rubino F (September?October 2009). "
"Metabolic" surgery for treatment of type 2 diabetes mellitus".
Endocrine Practice
.
15
(6): 624?31.
doi
:
10.4158/EP09170.RAR
.
PMID
19625245
.
- ^
Colucci RA (January 2011). "Bariatric surgery in patients with type 2 diabetes: a viable option".
Postgraduate Medicine
.
123
(1): 24?33.
doi
:
10.3810/pgm.2011.01.2242
.
PMID
21293081
.
S2CID
207551737
.
- ^
Dixon JB, le Roux CW, Rubino F, Zimmet P (June 2012). "Bariatric surgery for type 2 diabetes".
Lancet
.
379
(9833): 2300?11.
doi
:
10.1016/S0140-6736(12)60401-2
.
PMID
22683132
.
S2CID
5198462
.
- ^
Rubino F, Nathan DM, Eckel RH, Schauer PR, Alberti KG, Zimmet PZ, et al. (June 2016).
"Metabolic Surgery in the Treatment Algorithm for Type 2 Diabetes: A Joint Statement by International Diabetes Organizations"
.
Diabetes Care
.
39
(6): 861?77.
doi
:
10.2337/dc16-0236
.
PMID
27222544
.
- ^
Olaogun I, Farag M, Hamid P (2020).
"The Pathophysiology of Type 2 Diabetes Mellitus in Non-obese Individuals: An Overview of the Current Understanding"
.
Cureus
.
12
(4): e7614.
doi
:
10.7759/cureus.7614
.
ISSN
2168-8184
.
PMC
7213678
.
PMID
32399348
.
- ^
Salvatore T, Galiero R, Caturano A, Rinaldi L, Criscuolo L, Di Martino A, et al. (30 December 2022).
"Current Knowledge on the Pathophysiology of Lean/Normal-Weight Type 2 Diabetes"
.
International Journal of Molecular Sciences
.
24
(1): 658.
doi
:
10.3390/ijms24010658
.
ISSN
1422-0067
.
PMC
9820420
.
PMID
36614099
.
- ^
Vipin VA, Blesson CS, Yallampalli C (15 March 2022).
"Maternal low protein diet and fetal programming of lean type 2 diabetes"
.
World Journal of Diabetes
.
13
(3): 185?202.
doi
:
10.4239/wjd.v13.i3.185
.
ISSN
1948-9358
.
PMC
8984567
.
PMID
35432755
.
- ^
Wild S, Roglic G, Green A, Sicree R, King H (May 2004).
"Global prevalence of diabetes: estimates for the year 2000 and projections for 2030"
.
Diabetes Care
.
27
(5): 1047?53.
doi
:
10.2337/diacare.27.5.1047
.
PMID
15111519
.
- ^
a
b
c
d
e
f
g
h
Zajac J, Shrestha A, Patel P, Poretsky L (2009).
"The Main Events in the History of Diabetes Mellitus"
. In Poretsky L (ed.).
Principles of diabetes mellitus
(2nd ed.). New York: Springer. pp. 3?16.
ISBN
978-0-387-09840-1
.
OCLC
663097550
.
- ^
Sajida S (2021-01-26).
A Hand Book On Diabetes
. OrangeBooks Publication. p. 2.
- ^
a
b
Koutroumpakis E, Jozwik B, Aguilar D, Taegtmeyer H (March 2020).
"Strategies of Unloading the Failing Heart from Metabolic Stress"
.
The American Journal of Medicine
(Review).
133
(3): 290?296.
doi
:
10.1016/j.amjmed.2019.08.035
.
PMC
7054139
.
PMID
31520618
.
- ^
"Developing tools to help predict future risk for diabetes and heart attack"
.
Faculty of Biology, Medicine and Health
. Retrieved
2024-03-20
.
- ^
Zghebi SS, Mamas MA, Ashcroft DM, Salisbury C, Mallen CD, Chew-Graham CA, et al. (May 5, 2020).
"Development and validation of the DIabetes Severity SCOre (DISSCO) in 139 626 individuals with type 2 diabetes: a retrospective cohort study"
.
BMJ Open Diabetes Research & Care
.
8
(1): e000962.
doi
:
10.1136/bmjdrc-2019-000962
.
ISSN
2052-4897
.
PMC
7228474
.
PMID
32385076
.
- ^
"New tool for assessing the severity of type 2 diabetes could help personalise treatment and improve outcomes"
.
NIHR Evidence
(Plain English summary). National Institute for Health and Care Research. 2020-08-07.
doi
:
10.3310/alert_40652
.
S2CID
242997909
.
- ^
Zghebi SS, Mamas MA, Ashcroft DM, Salisbury C, Mallen CD, Chew-Graham CA, et al. (May 2020).
"Development and validation of the DIabetes Severity SCOre (DISSCO) in 139 626 individuals with type 2 diabetes: a retrospective cohort study"
.
BMJ Open Diabetes Research & Care
.
8
(1): e000962.
doi
:
10.1136/bmjdrc-2019-000962
.
PMC
7228474
.
PMID
32385076
.
Works cited
- Kahn CR, Ferris HA, O'Neill BT (2020). "Pathophysiology of Type 1 Diabetes Mellitus".
Williams Textbook of Endocrinology
(14 ed.). Elsevier. pp. 1349?1370.
- International Diabetes Federation (2021).
IDF Diabetes Atlas
(PDF)
(10 ed.). International Diabetes Federation.
ISBN
978-2-930229-98-0
. Retrieved
18 March
2022
.
External links
Classification
| |
---|
External resources
| |
---|